Insulin aspart, recombinant Subcutaneous and Phenazopyridine Plus
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Phenazopyridine Plus and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: butabarbital / hyoscyamine / phenazopyridine
Brand name:
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Phenazopyridine Tablets
- Insulin aspart, recombinant Subcutaneous-Phencyclidine
- Insulin aspart, recombinant Subcutaneous-Phendiet
- Insulin aspart, recombinant Subcutaneous-Phendiet-105
- Insulin aspart, recombinant Subcutaneous-Phendimetrazine
- Insulin aspart, recombinant Subcutaneous-Phendimetrazine Extended-Release Capsules
- Phenazopyridine Plus-Insulin degludec
- Phenazopyridine Plus-Insulin Degludec (U-100) Prefilled Pens
- Phenazopyridine Plus-Insulin Degludec (U-100) Vials
- Phenazopyridine Plus-Insulin Degludec (U-200) Prefilled Pens
- Phenazopyridine Plus-Insulin degludec and liraglutide
- Phenazopyridine Plus-Insulin degludec and liraglutide Subcutaneous